Abstract
The introduction of effective antipsychotic drugs in the early 1950s produced a revolution in the care of acute and chronic psychoses (Delay et al., 1952). Many patients with schizophrenia who previously would have been confined to mental hospitals for life were able to lead almost normal lives in the community, their psychotic symptoms being adequately controlled. This pharmacological miracle was not without its drawbacks. It soon became apparent that these drugs were not only attended by the usually recognized side effects such as cholestatic jaundice, but also had remarkable effect on the control of movement, i.e., on the extrapyramidal system. The first problem to be noted in this regard was drug-induced parkinsonism (Steck, 1954). Early on in their use it was felt that a drug’s antipsychotic action paralleled its ability to produce parkinsonism. The impassive facies, flexed posture, and other parkinsonian features soon became a commonplace finding in mental institutions. Initially, this did not cause undue concern as it was felt that this was a small price to pay for control of mentally disturbed patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Agnoli, R., Ruggiere, S., Falaschi, P., et al.,1980, Are the enkephalins involved in Parkinson’s disease, clinical and neuroendocrine responses to Naloxone administration, in: Neural Peptides and Neuronal Communications (E. Costa and M. Trabucchi, eds.), pp. 511–521, Raven Press, New York.
APA Task Force, 1980, Tardive dyskinesia: Summary of a task force report of the American Psychiatric Association, by the task force on late neurological effects on antipsychotic drugs, Am. J. Psychiatry 137: 1163–1172.
Ayd, F. J., Jr., 1961, A survey of drug-induced extrapyramidal reactions, DAMA 175: 1054–1060.
British Medical Association and the Pharmaceutical Society of Great Britain, 1985, British National Formulary, No. 4, pp. 123–124.
Burke, R. E., Fahn, S., Jankovic, J., Marsden, C. D., Lang, A. E., Gollomps, S., and Illson, J., 1982, Tardive dystonia: Late-onset and persistent dystonia caused by antipsychotic drugs, Neurology (NY) 32: 1335–1346.
Cotzias, G. C., Van Woert, M. H., and Schiffer, L. M., 1967, Aromatic amino acids and modification of parkinsonism, N. Engl. J. Med. 276: 374–379.
Crane, G. E., 1973, Persistent dyskinesia, Br. J. Psychiatry 122: 395–405.
Debontridder, O., 1980, Dystonic reactions after domperidone (letter), Lancet 2: 1259.
Degkwitz, R., 1969, Extrapyramidal motor disorders following long-term treatment with neuroleptic drugs, in: Psychotropic Drugs and Dysfunctions of the Basal Ganglia (G. E. Craine and R. J. Gardner, eds.), pp. 21–33, Public Health Service Publication No. 1938, Washington, DC.
Delay, J., Deniker, P., and Hari, J. M., 1952, Utilisation en therapeutique psychiatrique d’une phenothiazine d’action centrale elective, Ann. Med.-Psychol. 110:112–117. ’
De Silva, K. L., Muller, P. J., and Pearce, J., 1973, Acute drug-induced extrapyramidal syndromes, Practitioner 211: 316–320.
Duvoisin, R. C., 1967, Cholinergic—anticholinergic antagonism in parkinsonism, Arch. Neurol. 17: 124–136.
Duvoisin, R. C., and Yahr, M.D., 1965, Encephalitis and parkinsonism, Arch. Neurol. 12: 227–239.
Fahn, S., and David, E., 1972, Oral-facial-lingual dyskinesia due to anticholinergic medication, Trans. Am. Neurol. Assoc. 97: 277–279.
Fann, W. E., Sullivan, J. L., and Richman, B. W., 1976, Dyskinesias associated with tricyclic antidepressants, Br. J. Psychiatry 128: 490–493.
Kebabian, J. W., and Calne, D. B., 1979, Multiple receptors for dopamine, Nature 277: 93–96.
Klawans, H. L., Jr., 1973, The pharmacology of tardive dyskinesias, Am. J. Psychiatry 130: 82–86.
Klawans, H. L., and Rubovits, R., 1974, Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J. Neurol. Neurosurg. Psychiatry 37: 941–947.
Lautin, A., Stanley, M., Angrist, B., and Gershon, S., 1979, Extrapyramidal syndrome with sodium valproate, Br. Med. J. 2: 1035–1036.
Mackay, A. V. P., and Sheppard, G. P., 1979, Pharmacotherapeutic trials in tardive dyskinesia. Br. J. Psychiatry 135: 489–499.
Marsden, C. D., and Jenner, P., 1980, The pathophysiology of extrapyramidal side-effects of neuroleptic drugs, Psychol. Med. 10: 55–72.
Marsden, C. D., Tarsy, D., and Baldessarini, R. J., 1975, Spontaneous and drug-induced movement disorders in psychotic patients. in: Psychiatric Aspects of Neurologic Disease ( F. D. Benson and D. Blumer, eds.), pp. 219–266, Grune & Stratton, New York.
McDowell, F. H., and Sweet, R. D., 1976, in: Advances in Parkinsonism (W. Birkmayer and O. Hornykiewicz, eds.), pp. 603–612, Roche, Basel.
Mindham, R. H. S., 1978, The major tranquillizers, in: Side Effects of Drugs Annual ( M. N. G. Dukes, ed.), Elsevier, New York.
Moller-Nielsen, I., Christensen, A. V., and Fjalland, B., 1976, Receptor blockade and receptor super-sensitivity following neuroleptic treatment, in: Antipsychotic Drugs, Pharmacodynamics and Pharmacokinetics ( G. Sedval, B. Uvras, and B. Zotterman, eds.), pp. 257–260, Pergamon Press, Oxford.
Pearce, J., and Pearce, 1., 1971, Current concepts of parkinsonism, Postgrad. Med. J. 47: 794–799.
Pearce, J. M. S., 1977, Symptomatic parkinsonism, Postgrad. Med. J. 53: 726–728.
Pearce, J. M. S., 1978, Aetiology and natural history of Parkinson’s disease, Br. Med. J. 2: 1664–1670.
Pert, A., Rosenblatt, J. E., Sivit, C., Pert, C. B., and Bunney, W. E., Jr., 1978, Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity, Science 201: 171–173.
Riddoch, D., Jefferson, M., and Bickerstaff, E. R., 1971, Chorea and the oral contraceptives, Br. Med. J. 4: 217–218.
Sale, I., and Kalucy, R., 1981, Psychosis associated with oral contraceptive-induced chorea, Med. J. Aust. 1: 79–80.
Schonecker, M., 1957, Ein Eigentumliches Syndrom im Oralen Bereich bei Megaphen applikation, Nervenarzt 28: 35.
Simpson, G. M., Lee, J. H., Zoubok, B., and Gardos, G., 1979, A rating scale for tardive dyskinesia, Psychopharmacology 64: 171–179.
Steck, H., 1954, Le Syndrome extrapyramidal et di-encephalique au cours des traitements au largactil et an serpasil, Ann. Med.-Psychol. 112: 737–743.
Thach, B. T., Chase, T. N., and Bosma, J. F., 1975, Oral—facial dyskinesia associated with prolonged use of antihistamine decongestant, N. Engl. J. Med. 293: 486–488.
Yahr, M. D., Duvoisin, R. C., Schear, M. J., Barrett, R. E., and Hoehn, M. M., 1969, Treatment of parkinsonism with levodopa, Arch. Neurol. 21: 343–354.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Plenum Publishing Corporation
About this chapter
Cite this chapter
Pearce, J.M.S., Clough, C.C. (1986). Drug-Induced Movement Disorders. In: Shah, N.S., Donald, A.G. (eds) Movement Disorders. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5038-5_19
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5038-5_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5040-8
Online ISBN: 978-1-4684-5038-5
eBook Packages: Springer Book Archive